U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C24H27F2N5O4
Molecular Weight 487.4991
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PEMIGATINIB

SMILES

CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C5=C(F)C(OC)=CC(OC)=C5F

InChI

InChIKey=HCDMJFOHIXMBOV-UHFFFAOYSA-N
InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)

HIDE SMILES / InChI

Molecular Formula C24H27F2N5O4
Molecular Weight 487.4991
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pemigatinib, an oral kinases inhibitor, was approved under the brand name PEMAZYRE for the treatment of adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion. The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. The drug inhibited FGFR1-3 phosphorylation and signaling and decreased cell viability in cancer cell lines with activating FGFR amplification and fusions that resulted in constitutive activation of FGFR signaling.

CNS Activity

Curator's Comment: pemigatinib crossed the blood-brain barrier at low levels after IV administration.

Originator

Curator's Comment: was synthesized at Incyte Corporation (Wilmington, DE).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P11362|||Q14307|||Q9UDF2
Gene ID: 2260.0
Gene Symbol: FGFR1
Target Organism: Homo sapiens (Human)
0.4 nM [IC50]
Target ID: P21802|||Q14301|||Q1KHY5|||Q9NZU3|||Q9UIH8
Gene ID: 2263.0
Gene Symbol: FGFR2
Target Organism: Homo sapiens (Human)
0.5 nM [IC50]
1.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PEMAZYRE

Approved Use

PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
236 nM
13.5 mg 1 times / day steady-state, oral
dose: 13.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PEMIGATINIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2620 nM × h
13.5 mg 1 times / day steady-state, oral
dose: 13.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PEMIGATINIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.4 h
13.5 mg 1 times / day steady-state, oral
dose: 13.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PEMIGATINIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN

Sample Use Guides

The recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy, in 21-day cycles. Continue treatment until disease progression or unacceptable toxicity occurs
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Tue Apr 01 18:17:36 GMT 2025
Edited
by admin
on Tue Apr 01 18:17:36 GMT 2025
Record UNII
Y6BX7BL23K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
2H-PYRROLO(3',2':5,6)PYRIDO(4,3-D)PYRIMIDIN-2-ONE, 3-(2,6-DIFLUORO-3,5-DIMETHOXYPHENYL)-1-ETHYL-1,3,4,7-TETRAHYDRO-8-(4-MORPHOLINYLMETHYL)-
Preferred Name English
PEMIGATINIB
INN   USAN  
Official Name English
3-(2,6-DIFLUORO-3,5-DIMETHOXYPHENYL)-1-ETHYL-8-(MORPHOLIN-4-YLMETHYL)-1,3,4,7-TETRAHYDRO-2H-PYRROLO(3',2':5,6)PYRIDO(4,3-D)PYRIMIDIN-2-ONE
Systematic Name English
INCB-054828
Common Name English
PEMIGATINIB [USAN]
Common Name English
PEMIGATINIB [JAN]
Common Name English
Pemigatinib [WHO-DD]
Common Name English
PEMIGATINIB [ORANGE BOOK]
Common Name English
FGFR INHIBITOR INCB054828
Common Name English
pemigatinib [INN]
Common Name English
PEMIGATINIB [MI]
Common Name English
INCB054828
Code English
PEMAZYRE
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 624117
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
FDA ORPHAN DRUG 696419
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
NCI_THESAURUS C129825
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
EU-Orphan Drug EU/3/18/2066
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
NCI_THESAURUS C1967
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
Code System Code Type Description
INN
10712
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
CAS
1513857-77-6
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
MERCK INDEX
m12200
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
PUBCHEM
86705695
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
SMS_ID
100000181126
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
RXCUI
2359268
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
DRUG BANK
DB15102
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
USAN
FG-16
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
DRUG CENTRAL
5390
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
FDA UNII
Y6BX7BL23K
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
EPA CompTox
DTXSID501027955
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
DAILYMED
Y6BX7BL23K
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
WIKIPEDIA
Pemigatinib
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
NCI_THESAURUS
C121553
Created by admin on Tue Apr 01 18:17:36 GMT 2025 , Edited by admin on Tue Apr 01 18:17:36 GMT 2025
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
FECAL
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BINDER->LIGAND
In vitro, pemigatinib was 90.6% bound to human plasma proteins at concentrations ranging from 1 to 10 ?M.
BINDING
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
EXCRETED UNCHANGED
URINE
TARGET -> INHIBITOR
IC50
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC